A review on treatment of high-risk neuroblastoma

TANG Suo-Qin

doi:10.7499/j.issn.1008-8830.2014.02.001

PDF(1053 KB)

Chinese Journal of Contemporary Pediatrics ›› 2014, Vol. 16 ›› Issue (2) : 103-107. DOI: 10.7499/j.issn.1008-8830.2014.02.001

SPECIALIST LECTURE

A review on treatment of high-risk neuroblastoma

TANG Suo-Qin

Author information +

History +

Abstract

So far treatment of advanced neuroblastoma is still difficult, due to its high malignancy. Currently comprehensive therapies, including high-dose multi-drug chemotherapy, surgery, stem cell transplantation, radiation, biological therapy and immune therapy as well as target therapy dominant the treatment of this disease, and we hereby introduce the latest development of treatment protocols for this disease.

Key words

Neuroblastoma / Chemotherapy / Immunotharapy / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

TANG Suo-Qin. A review on treatment of high-risk neuroblastoma[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(2): 103-107 https://doi.org/10.7499/j.issn.1008-8830.2014.02.001

References

[1] Mattano LA Jr, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptasepolymerase chain reaction[J]. Cancer Res, 1992, 52(17): 4701-4705.
[2] Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies[J]. J Clin Oncol, 1996, 14(9): 2417-2426.
[3] Vogelzang NJ, Benowitz SI, Adams S, et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology[J]. J Clin Oncol, 2012, 30(1): 88-109.
[4] Castel V, Tovar JA, Costa E, et al. The role of surgery in stage IV neuroblastoma[J]. J Pediatr Surg, 2002, 37(11): 1574-1578.
[5] Wilson JS, Gains JE, Moroz V, et al. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma[J]. Eur J Cancer, 2013. doi: 10.1016/ j.ejca.2013.11.016.[Epub ahead of print].
[6] Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for highrisk neuroblastoma (COG A3973): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(10): 999-1008.
[7] Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma[J]. J Clin Oncol, 1998, 16(6): 2169-2180.
[8] Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients withneuroblastoma[J]. Eur J Cancer, 1995, 31A(2): 261-267.
[9] Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
[10] Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy[J]. J Pediatr Hematol Oncol, 2013, 35(5): 337-347.
[11] Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for highrisk neuroblastoma: High incidence of endocrine and growth problems[J]. Bone Marrow Transplant, 2014. doi: 10.1038/ bmt.2013.218.[Epub ahead of print].